Onconova Therapeutics Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa, was presented on Saturday, June 3, 2023, during the “Melanoma/Skin Cancers” session.
Onconova Therapeutics announced that the first participant has been dosed in an investigator-sponsored Phase 2 trial of oral rigosertib plus the PD-1 inhibitor pembrolizumab in patients with metastatic melanoma who have progressed on prior PD-1/L1 inhibitor therapy.
GET IN TOUCH
12 Penns Trail
Newtown, PA 18940
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.